<DOC>
	<DOCNO>NCT00097942</DOCNO>
	<brief_summary>Standard antipsychotic drug regimen fully address impact cognitive symptom associate schizophrenia . The NMDA receptor connect pathophysiology schizophrenia . Memantine uncompetitive NMDA receptor antagonist . It hypothesize adjunctive therapy memantine reduce NMDA receptor hyperactivity , improve signal noise ratio thereby improve cognitive symptom .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Memantine Adjunctive Treatment Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>DSMIV diagnose Schizophrenia schizoaffective disorder stable antipsychotic regimen Brief Psychiatric Rating Scale ( BPRS ) total score great equal 26 great equal 4 least one item Secondary diagnosis Bipolar I disorder Suicidal history Organic brain disease Dementia History substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>memantine</keyword>
	<keyword>adjunctive therapy</keyword>
	<keyword>schizophrenia</keyword>
</DOC>